期刊文献+

PD-1抑制剂及西达本胺联合GEMOX方案治疗具有滤泡辅助T细胞表型的淋巴结外周T细胞淋巴瘤1例并文献复习

Programmed-death receptor 1 inhibitor and chidamide combined with GEMOX regimen in treatment of lymph node peripheral T-cell lymphoma with follicular helper-T cell phenotype:report of 1 case and review of literature
原文传递
导出
摘要 目的探讨具有滤泡辅助T细胞(TFH)表型的淋巴结外周T细胞淋巴瘤的临床特点、诊断及治疗。方法回顾分析威海市立医院2021年10月收治的1例具有TFH表型的淋巴结外周T细胞淋巴瘤患者临床资料,并进行相关文献复习。结果患者经淋巴结活组织检查病理诊断为具有TFH表型的淋巴结外周T细胞淋巴瘤,前期给予7个疗程CHOPE方案治疗,行PET-CT检查未获得完全缓解,后改为程序性死亡受体1(PD-1)抑制剂及西达本胺联合GEMOX方案治疗4个疗程,再次行PET-CT评效达完全缓解。继以西达本胺维持治疗,监测病情持续稳定。结论具有TFH表型的淋巴结外周T细胞淋巴瘤患者采用PD-1抑制剂及西达本胺联合化疗可取得良好疗效。
作者 王晓毅 高健 于洁 李伟华 Wang Xiaoyi;Gao Jian;Yu Jie;Li Weihua(Department of Hematology,Weihai Municipal Hospital,Weihai 264200,China)
出处 《白血病.淋巴瘤》 CAS 2023年第11期692-693,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献2

二级参考文献14

  • 1周生余,石远凯,何小慧,张频,董梅,黄鼎智,杨建良,张长弓,刘鹏,杨晟,冯奉仪.DICE方案治疗复发或耐药中高度恶性非霍奇金淋巴瘤[J].癌症,2005,24(4):465-469. 被引量:29
  • 2杨渤彦,勇威本,朱军,郑文,张运涛,王小沛,孟松娘.弥漫性大B细胞淋巴瘤的临床特征及预后影响因素分析[J].中华肿瘤杂志,2005,27(3):174-176. 被引量:37
  • 3于慧,洪小南,李进,彭丽萍,叶兰.侵袭性非霍奇金淋巴瘤预后相关因素分析[J].中华肿瘤杂志,2007,29(6):461-463. 被引量:12
  • 4Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma[J]. Cancer, 2008, 112(4) :831-836.
  • 5Rodrguez J, Gutierrez A, Palacios A, et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma[ J]. Leuk Lymphoma, 2007, 48 ( 11 ) :2172-2178.
  • 6Sirohi B, Cunningham D, Norman A, et al. Gemcitabine, cisplafin and methylprednisolone ( GEM-P ) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL) [ J]. Hematology, 2007, 12(2) : 149-153.
  • 7Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome[J]. Ann Oncol, 2010, 21(4) :860-863.
  • 8Pasricha SR, Grigg A, Catalano J, et al. A muhicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma [J], Cancer, 2008, 113(11) :3192-3198.
  • 9E1 Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy[ J]. Ann Oncol, 2007,18 (8) : 1363-1368.
  • 10Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemeitabine, earboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi- center phase 11 study by the Puget Sound Oncology Consortium [ J]. Leuk Lymphoma, 2010, 51 (8) : 1523-1529.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部